Recent Trials of Interest, Barriers to Radioligand Therapy, and Nuances in PSMA Engagement

In the fifth segment of the roundtable discussion on radioligand treatment for prostate cancer, the panel moves into the impact of recent clinical trials, such as the VISION study, and explores the future potential of radioligand therapy for hormone-sensitive and metastatic prostate cancer. They discuss barriers to treatment, patient management, and the exciting advancements in new targets and novel therapies.

Watch the final part of this series: Sitting Eye to Eye With Patients: Addressing Logistics When Things Don’t Go as Planned